Nitya Alluri

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial”.

Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial

Journal of Clinical Oncology(2025)10.1200/jco-24-01710

N/A

0.458DataRank · unranked

9 citations

Katherine A. Guthrie, Benjamin Tan, Crystal S. Denlinger, Marwan Fakih, Michael J. Overman +15 more

Effects of a Guideline-Informed Clinical Decision Support System Intervention to Improve Colony-Stimulating Factor Prescribing

JAMA Network Open(2022)10.1001/jamanetworkopen.2022.38191

N/A

0.362DataRank · unranked

6 citations

Aasthaa Bansal, Sean D. Sullivan, Gary H. Lyman, William E. Barlow, Kathryn B. Arnold +11 more

Neoplastic and blood-based biomarkers of response in patients with advanced endometrial cancer: Results from NRG GY012.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5525

N/A

0.104DataRank · unranked

1 citations

Andrew B. Nixon, Danielle Enserro, David Bender, B.J. Rimel, Matthew A. Powell +12 more

A randomized phase II study comparing single-agent olaparib, single-agent cediranib, and the combinations of cediranib/olaparib, olaparib/durvalumab (MEDI4736), cediranib/durvalumab (MEDI4736), and olaparib/AZD5363 (capivasertib) in women with recurrent, persistent, or metastatic endometrial cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps5629

N/A

0DataRank · unranked

1 citations

David Bender, Danielle Enserro, Shannon N. Westin, Debra L. Richardson, Laura L. Holman +10 more

A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.140

N/A

0DataRank · unranked

7 citations

Katherine A. Guthrie, Scott Kopetz, Benjamin Tan, Crystal S. Denlinger, Marwan Fakih +15 more

A pragmatic cluster-randomized trial of a standing physician order entry intervention for colony stimulating factor use among patients at intermediate risk for febrile neutropenia (SWOG S1415CD).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.1518

N/A

0DataRank · unranked

1 citations

Aasthaa Bansal, Sean D. Sullivan, Gary H. Lyman, William E. Barlow, Kathryn B. Arnold +10 more

A pragmatic cluster-randomized trial of a computerized clinical decision support system to improve colony stimulating factor prescribing for patients with cancer receiving myelosuppressive chemotherapy (SWOG S1415CD).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.1525

N/A

0DataRank · unranked

1 citations

Aasthaa Bansal, Sean D. Sullivan, Gary H. Lyman, William E. Barlow, Kathryn B. Arnold +10 more